ADC Process Development &
Conjugation CMC Consulting
Build an ADC manufacturing path shaped around conjugation,
purification, containment, and late-stage control strategy.
Modalities Supported
- Auristatin (MMAE / MMAF)
- Maytansinoid (DM1 / DM4)
- Topoisomerase I (DXd / SN-38)
- Cleavable Linkers
- Non-Cleavable Linkers
- Site-Specific Platforms
- OEB 4 / 5 Compounds
ADC Process Development Conjugation Strategy Built for Scale, Control, and CMC Review
ADC manufacturing performance depends on the combined behavior of the antibody, linker-payload, conjugation chemistry, purification train, and containment model. DES Pharma supports sponsors developing cleavable and non-cleavable ADC platforms (including auristatin, maytansinoid, and topoisomerase I payload systems) through process design that works at scale and supports CMC review. We help teams turn early conjugation concepts into repeatable manufacturing processes with defined control points for DAR, drug load distribution, residual free payload, unconjugated antibody, aggregation, and yield.
Whether the program uses lysine conjugation, reduced interchain cysteine conjugation, or a site-specific platform, we focus on process decisions that support batch consistency and make later analytical and validation work easier to manage. Our support covers reaction development, quench strategy, purification design, formulation interfaces, tech transfer packages, and late-stage process characterization. The goal is to build an ADC process that is phase-appropriate, scalable, and ready to support clinical supply, PPQ planning, and commercial control strategy.
ADC Conjugation & Manufacturing Focus Areas
Where ADC programs most often lose time, and how we address them
We focus on the parts of ADC process development where programs most often lose time: conjugation reproducibility, DAR distribution, free payload clearance, aggregate control, hold-step stability, and transfer into contained GMP operations.
Phase-Appropriate CMC Approach
Cutting Out Excess & Risks
Across Every Development Stage
Phase-appropriate process development that ensures batch consistency, data-driven improvements, and efficient progress from pre-clinical through commercial ADC launch.
Pre-Clinical
Begin with the end state in mind: build ADC conjugation foundations that scale
- Linker-payload selection and compatibility screening for the candidate antibody and intended DAR range
- Early DAR target setting and drug load distribution planning
- Purification sequence development to remove free payload, residual linker-payload, and unconjugated antibody
- Small-scale scale-up models for reaction reproducibility and material balance tracking
- Conjugation chemistry feasibility for lysine, reduced cysteine, and site-specific platforms
- Reaction condition screening for stoichiometry, reduction, quench, and solvent exposure control
- Formulation compatibility assessment for linker stability and process hold conditions
- Potent compound handling strategy aligned with process development and analytical sampling needs
Phase 1 / 2
Lay the groundwork for robust clinical supply and commercial product launch
- Tech transfer package development for conjugation, purification, and in-process controls
- Facility fit assessment for contained conjugation suites, material flow, and personnel flow
- Batch record review and support for engineering, toxicology, and GMP clinical lots
- Stability study design aligned with linker stability, payload release risk, and formulation conditions
- Clinical manufacturing sampling plans linked to DAR, purity, aggregation, and residual payload control
- Raw material qualification strategy for antibody bulk, linker-payload, and critical process reagents
- Process parameter range refinement with phase-appropriate statistical evaluation
- Comparability planning for process changes, site changes, or conjugation platform updates
Pre-Commercial Launch
Ensure process control, consistent product quality, and submission readiness
- Process characterization studies for reaction robustness and purification capability
- Control strategy definition for DAR distribution, free payload, aggregates, and residual impurities
- Resin and membrane lifetime studies for ADC purification steps
- Filing-ready CMC narratives for process description, controls, and lifecycle justification
- Scale-down model qualification for conjugation performance, clearance, and hold-time evaluation
- PPQ planning support for contained manufacturing operations and commercial batch documentation
- Shipping and handling validation for drug substance and formulated drug product
- Pre-approval inspection readiness for ADC manufacturing, containment, and data integrity expectations
Post-Commercial Support
Maintain compliance, support lifecycle management, and expand market reach
- Change evaluation for antibody source, linker-payload lot, scale, or site updates
- Lifecycle management for purification materials and process parameter ranges
- Inspection response support for process performance and product quality questions
- Continued process verification support linked to commercial quality trends
- Comparability packages for post-approval manufacturing improvements
- Due diligence support for investors, partners, and manufacturing expansion decisions
Integrated CMC Strategy Integrated ADC Process Strategy
ADC process work is more effective when conjugation strategy, analytical planning, and GMP operating requirements are built as one connected program. DES Pharma helps teams line these pieces up early so later development, transfer, and filing work move more smoothly. We focus on the factors that most often determine whether an ADC process scales well: DAR distribution, residual free payload clearance, unconjugated antibody control, aggregate management, hold-step stability, and containment fit.
Conjugation Strategy Selection
Evaluation of lysine, cysteine, and site-specific platforms against reproducibility, heterogeneity, and transferability criteria, matched to the antibody format, intended DAR, and downstream analytical strategy.
DAR Control & Distribution
Setting DAR targets informed by product performance and manufacturing consistency. Building control approaches that connect reaction conditions to drug load outcomes and remain defensible through IND amendment and BLA filing.
Purification Design
Designing purification trains for payload clearance, unconjugated antibody removal, aggregate reduction, and yield balance, including resin selection, step sequencing, and in-process hold compatibility.
Scale-Up Planning
Addressing mixing regime, hold-time assumptions, sampling access, and equipment constraints across bench, clinical, and commercial scales. Developing scale-down models and transfer criteria for CDMO operations.
Containment Readiness
Assessing OEB requirements for the payload class, identifying contained conjugation suite options, developing potent compound handling SOPs, and planning cleaning validation approaches for ADC manufacturing equipment.
Why DES Pharma for ADC Process Development
Rational Design, Reliable Results
Emphasizing Process Design & Product Quality
Our approach integrates conjugation science, manufacturing realism, and regulatory CMC thinking from the first process discussion.
Phase-Appropriate Design
Process plans that support the current development stage without sacrificing the structural decisions needed for the eventual commercial process.
Integrated Process & Analytics
Analytical planning built alongside process decisions so QC method development, specification setting, and stability work are easier to execute at each phase transition.
Manufacturing Realism
Recommendations grounded in plant execution realities (equipment fit, batch scale, hold logistics, and GMP documentation), not bench chemistry assumptions alone.
Containment-Aware Planning
Potent compound handling, OEB classification, suite selection, and cleaning validation integrated into process design from the start, not retrofitted at tech transfer.
Transfer-Ready Documentation
Tech transfer packages, CDMO communication materials, engineering lot reports, and PPQ preparation documents built to be usable by operations teams, not just internal scientists.
Commercial Pathway Planning
Scale, comparability, control strategy, and filing readiness are addressed as a coherent program, so late-stage transitions and post-approval changes are planned, not reactive.
Our Approach
Supply Planning & Commercial Readiness
Recommended Process Planning Framework
A structured approach to ADC process development that connects early conjugation decisions to later-stage manufacturing control, regulatory filing, and commercial lifecycle management.
Define Product Intent
Establish the target DAR range, conjugation approach, payload class, and key quality attribute risks that will govern process design decisions.
Map the Reaction Strategy
Define stoichiometry, reduction state, quench logic, solvent exposure parameters, and in-process sampling points to establish a reproducible conjugation sequence.
Design the Purification Train
Sequence purification steps for free payload removal, unconjugated antibody control, aggregate management, and yield balance, with step-specific performance targets.
Link to Analytics
Select in-process and release methods capable of monitoring process outputs and supporting future specifications aligned with ICH Q6B and analytical lifecycle expectations under ICH Q14 / Q2(R2).
Assess GMP Execution
Evaluate containment needs, equipment fit, material flow, cleaning strategy, and batch record implications before transfer to a GMP manufacturing environment.
Plan for Scale & Lifecycle
Frame tech transfer expectations, process characterization study scope, PPQ planning, and post-approval change management strategy as a connected CMC lifecycle program.
Get Started Build Your ADC Process Strategy for Scale, Control, and Filing Readiness
Connect with our ADC process development team to discuss your conjugation platform, DAR control approach, or commercial manufacturing pathway.